Publications (61) View all

  • Source
    Article: Quality control of leucocyte-reduced blood components: overestimation of WBC content due to nucleated red blood cells.
    J C Fischer, R Moog, G Giers
    [show abstract] [hide abstract]
    ABSTRACT: Most methods for quality control of white blood cell (WBC) depletion in blood products are based on flow cytometric techniques. Nearly all commercial kits are based on propidium iodide staining of the DNA and subsequently counting those DNA based events as residual WBC. Here, we could show that a substantial proportion of those events are derived from nucleated red blood cells and therefore not specific for WBCs (e.g. in erythrocyte products 30%). We developed a flow cytometric method for residual WBC counting applying simultaneous DNA- and WBC-specific surface staining to enable this.
    Vox Sanguinis 05/2011; 102(1):79-81. · 2.86 Impact Factor
  • Article: Soluble CD40 ligand in stem cell products of autologous donors.
    F Wenzel, W Günther, J M Rox, J C Fischer, G Giers
    Transfusion 01/2011; 51(1):226-7. · 3.22 Impact Factor
  • Article: The embryo's cystatin C and F expression functions as a protective mechanism against the maternal proteinase cathepsin S in mice.
    D M Baston-Buest, A Schanz, S Buest, J C Fischer, J S Kruessel, A P Hess
    [show abstract] [hide abstract]
    ABSTRACT: A successful implantation of a mammalian embryo into the maternal endometrium depends on a highly synchronized fetal-maternal dialogue involving chemokines, growth factors, and matrix-modifying enzymes. A growing body of evidence suggests an important role for proteinases playing a role in matrix degeneration and enhancing the embryo's invasive capacity and influencing the mother's immunological status in favor of the conceptus. This study focused on the expression of cathepsin S (CTSS) and its inhibitors in the murine fetal-maternal interface as well as the detection of the cellular sources of either proteinase and inhibitors. Nested RT-PCR for detection of embryonic mRNAs, immunohistochemistry of maternal and fetal tissues in B6C3F1 mice, and FACS analysis for determination of immunocompetent cell population were applied. This study shows that the cysteine proteinase CTSS is upregulated in the stroma of the implantation site, and that pregnancy induces an influx of CTSS-positive uterine natural killer cells. Compared to maternal tissues, the CTSS inhibitors cystatin F and C, but not the proteinase itself, are expressed in blastocysts. In conclusion, CTSS underlies a hormonal regulation in the maternal tissue and therewith most likely supports the embryonic implantation. The invading embryo regulates the depth of its own invasion through the expression of the cathepsin inhibitors and furthermore, interleukin-6 to activate CTSS in maternal tissues. Additionally, the observed decrease in CD3(+) cells leads to the hypothesis that cells of the cytotoxic T-cell group are down-regulated in the decidua to support the implantation and ensure the survival of the embryo.
    Reproduction 04/2010; 139(4):741-8. · 2.58 Impact Factor
  • Article: Zelltherapie bei Knochenheilungsstörungen
    M. Jäger, P. Hernigou, C. Zilkens, M. Herten, J. Fischer, R. Krauspe
    [show abstract] [hide abstract]
    ABSTRACT: Neben stabilisierenden Osteosynthesetechniken und der autologen Knochentransplantation spielen Orthobiologika bei der Behandlung von Knochenheilungsstörungen eine zunehmende Rolle. Derzeit kommen hierbei v.a. Wachstumsfaktoren zum Einsatz. Zudem mehren sich Berichte, dass Zelltherapeutika die lokale Knochenregeneration fördern. Aus ethischen und biologischen Gründen ist die klinische Anwendung von Progenitorzellen am Bewegungsapparat zurzeit auf autologe, postpartale Stammzellen beschränkt. Dabei zeigte v.a. die intraoperative einzeitige Zelltherapie mit autologen Progenitorzellen in ersten klinischen Studien positive Ergebnisse. Anhand einer Literaturrecherche sowie eigenen Erfahrungen an 75Patienten mit Knochendefekten oder -heilungsstörungen wird eine aktuelle Übersicht über die biologischen Hintergründe und die Besonderheiten der klinischen Anwendung einer Zelltherapie zur Behandlung ossärer Substanzdefekte gegeben. Die meisten klinischen Studien berichteten über eine erfolgreiche Knochenregeneration nach Applikation von Mischzellpopulationen aus Knochenmark. In addition to stabilizing osteosynthesis and autologous bone transplantation, so-called orthobiologics are playing an increasing role in the treatment of bone-healing disorders. Besides the application of different growth factors, new data in the literature suggest that cell therapeutic agents promote local bone regeneration. Due to ethical and biological considerations, clinical application of progenitor cells for the musculoskeletal system is limited to autologous postpartum stem cells. Here in particular, cell therapy with autologous progenitor cells in one surgical session has delivered first promising results. Based on a review of the literature and on our own experience with 75patients, this article reviews the rationale and characteristics of the clinical application of cell therapy for the treatment of bony substance defects. Most clinical trials report successful bone regeneration after the application of mixed cell populations from bone marrow. SchlüsselwörterKnochendefekt-Knochenheilungsstörung-Zelltherapie-Stammzelle-Osteoblast KeywordsBone substance defect-Bone healing defect-Cell therapy-Stem cell-Osteoblast
    Der Orthopäde 04/2012; 39(4):449-464. · 0.51 Impact Factor
  • Source
    Article: [Cell therapy in bone-healing disorders].
    M Jäger, P Hernigou, C Zilkens, M Herten, J Fischer, R Krauspe
    [show abstract] [hide abstract]
    ABSTRACT: In addition to stabilizing osteosynthesis and autologous bone transplantation, so-called orthobiologics are playing an increasing role in the treatment of bone-healing disorders. Besides the application of different growth factors, new data in the literature suggest that cell therapeutic agents promote local bone regeneration. Due to ethical and biological considerations, clinical application of progenitor cells for the musculoskeletal system is limited to autologous postpartum stem cells. Here in particular, cell therapy with autologous progenitor cells in one surgical session has delivered first promising results. Based on a review of the literature and on our own experience with 75 patients, this article reviews the rationale and characteristics of the clinical application of cell therapy for the treatment of bony substance defects. Most clinical trials report successful bone regeneration after the application of mixed cell populations from bone marrow.
    Der Orthopäde 02/2010; 39(4):449-62; quiz 463. · 0.51 Impact Factor

Following (20) See all

Followers (25) See all

Browse more researchers